Samsung Bioepis Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Samsung Bioepis Co., Ltd.
Samsung Bioepis Quiet On Launch Date After EU Soliris Biosimilar Approval
Samsung Bioepis responded to Generics Bulletin enquiries following its EU-wide approval for a biosimilar to AstraZeneca’s Soliris.
Samsung Bioepis Biosimilars Report Sees Lower Price Boosting Uptake
Samsung Bioepis has published the first in a planned series of reports on the US biosimilars market, including insights into pricing, uptake and market share for various biosimilars.
Lilly Migraine Deal Gives AffaMed New Mojo In Changing China: Video Interview
A mega deal with Eli Lilly to exclusively market, promote and distribute Emgality (galcanezumab) in China for migraine prevention offers a critical opportunity for C-Bridge backed AffaMed in an untapped, large market, CFO Vijay Karwal told Scrip in an exclusive video interview on the sidelines of EBD's Asia Bio Partnering Forum.
Will Biosimilar Competition And Product-Hopping Save Regeneron’s Eylea Or Cancel Each Other Out?
Biosimilar entrants look to help protect Regeneron’s currently marketed form of Eylea from the US’s new price negotiation law. But it likely hinges on how CMS views the company’s product-hopping plan.
- Large Molecule
- Other Names / Subsidiaries
- Samsung Biologics
- Samsung Bioepis JV
- Samsung Bioepis BR Pharmaceutical LTDA
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.